Edwards Lifesciences Corp (EW)vsIradimed Co (IRMD)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
IRMD
Iradimed Co
$93.07
-0.53%
HEALTHCARE · Cap: $1.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 7206% more annual revenue ($6.30B vs $86.28M). IRMD leads profitability with a 27.4% profit margin vs 17.4%. EW appears more attractively valued with a PEG of 2.05. IRMD earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
IRMD
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Intrinsic value data unavailable for IRMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Strong operational efficiency at 32.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Keeps 27 of every $100 in revenue as profit
Earnings expanding 22.1% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Trading at 12.1x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 32.9%. Revenue growth of 12.6% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, Piotroski F-Score. A P/E of 50.3x leaves little room for execution misses.
Key Dynamics to Monitor
EW profiles as a growth stock while IRMD is a mature play — different risk/reward profiles.
IRMD carries more volatility with a beta of 0.91 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
IRMD generates stronger free cash flow (8M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 61/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?